Research at Oslo University Hospital

Mev Dominguez-Valentin from The Department of Tumor Biology is the first author of the article “Mortality by age, gene and gender in carriers of pathogenic mismatch repair gene variants receiving surveillance for early cancer diagnosis and treatment: A report from the Prospective Lynch Syndrome Database”, recently published in eClinicalMedicine, part of The Lancet Discovery Science. 

Researchers at Oslo University Hospital and at Wihuri Research Institute in Finland have identified persistent changes in LDL three months after hospitalization with severe COVID-19. Both the composition of the particle and inflammatory capacity have been altered and these alterations could contribute to an increased risk of developing heart disease later in life. The results have been published in the prestigious Journal of Infection. 
Senior author is Bente Halvorsen from the Research Institute of Internal Medicine.

Åslaug Helland has been elected as a member of the prestigious Norwegian Academy of Science and Letters. Altogether, four new members are welcomed to the Academy’s Natural Sciences Division in 2023, and Åslaug Helland will join the Medical Sciences group. She will be formally presented with her diploma during a ceremony at the Academy of Science and Letters Annual Meeting, which will take place on Wednesday 3 May.
Commenting on her election, Åslaug Helland says: “I’m truly honored and grateful to be nominated and elected as a member of the prestigious Norwegian Academy of Science and Letters. I look forward to participating in and contributing to Academy activities”.

RADFORSK investment foundation has granted NOK 15 mill. for a new research and development project in targeted and personalized radiopharmacy, TARACAN - "TArgeted RAdionuclide Therapy (TRT) for CANcer". The project will take place at the Division of Cancer Medicine and Division of Radiology and Nuclear Medicine at Oslo University Hospital and will be led by Asta Juzeniene at the Institute for Cancer Research. In addition, the clinicians Øyvind Bruland and Mona Elisabeth Revheim will participate in the project. The project has gained attention through a report in the popular medical newspaper "Dagens Medisin".

The Laboratory of Adaptive Immunity and Homeostasis, headed by Jan Terje Andersen, is at the forefront of studies on how a broadly expressed receptor named the neonatal Fc receptor (FcRn) acts as regulator of albumin and IgG antibody transport at different body sites.

The research group has signed a framework agreement with Roche Diagnostics GmbH and entered a research collaboration with the aim to gain a deeper understanding on how FcRn-targeted molecules are handled in both in vitro and in vivo systems.

The Colorectal Cancer Research Network is an international collaboration working towards an increased understanding of the mechanisms behind colorectal cancer, with the aim of improving treatment options. The Founders are connected to two of the leading Universities in the UK and the Institute for Cancer Genetics and Informatics at Oslo University hospital.
Håvard Danielsen and colleagues from the University of Oxford would like to invite you to a meeting about current practice, prediction and metastases for colon and rectal cancer, held in Oxford 30-31 March 2023.

A new call has been made for research funds from the National Program for Clinical Treatment Research in the Specialist Health Service (KLINBEFORSK). The regional health organizations announce about NOK 180 million for national clinical treatment studies in 2023.
For all applications, there are requirements for participation from clinical research environments in all health regions, provision for equal access for patients nationally and user participation.
In this year's call, priority will be given to applications within clinical treatment research for rare diseases.

Application deadline - May 31st 2023 4.00 PM

Oslo University Hospital leads and sponsor the EU-SolidAct platform trial with Professor Marius Trøseid as Chief Investigator and medical responsible, and Dr. Inge Christoffer Olsen as Head of Operations and Work Package leader in the overarching EU-project EU-RESPONSE.
The first drug tested on EU-SolidAct is baricitinib, a tablet approved for the treatment of rheumatoid arthritis, atopic dermatitis, and alopecia areata. Results of the Bari-SolidAct clinical trial, conducted in 14 European countries, was published in Critical Care on January 10th 2023.
While this trial was stopped early due to external evidence and is therefore underpowered to assess survival benefit, a possible safety signal in vaccinated participants, who were older with more comorbidities, was observed.

Stroke is the second leading cause of death worldwide and a major cause of disability related to both functional and cognitive impairments. A recent study, part of the Nor-COAST study, and from the Department of Radiology and Nuclear Medicine, set out to investigate the link between post stroke neurocognitive disorder (NCD) and advanced brain ageing. The results have recently been published in Neurobiology of Aging, with Eva Birgitte Aamodt (photo) as first author.